BriaCell Therapeutics Corp. (BCTX) Cash & Equivalents (2019 - 2026)

BriaCell Therapeutics has reported Cash & Equivalents for 8 years, with the latest figure at $22.8 million in Q2 2026.

• Quarterly Cash & Equivalents rose 83.02% year-over-year to $22.8 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $22.8 million (up 83.02% YoY) and the FY2025 annual result came in at $17.9 million, up 1972.44% from the prior year.
• Cash & Equivalents retreated to $22.8 million in Q2 2026 per BCTX's latest filing, from $29.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $48.0 million in Q1 2022 and troughed at $862089.0 in Q3 2024.
• A 5-year average of $21.1 million and a median of $19.6 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents surged 805908.48% in 2022, then tumbled 96.68% in 2024.
• Over 5 years, Cash & Equivalents stood at $37.5 million in 2022, then tumbled by 63.56% to $13.6 million in 2023, then plunged by 57.55% to $5.8 million in 2024, then jumped by 75.68% to $10.2 million in 2025, then soared by 124.1% to $22.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $22.8 million, $29.9 million, and $10.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.